Abstract
Recommendations on indications for allogeneic haematopoietic SCT have been presented, but transplantation techniques remain poorly standardized. Pre-transplant risk factors are well defined, and reported outcomes vary markedly among patients with similar risk characteristics. It would be of importance to know the impact of differences in treatment procedures. To study properly the different components of allogeneic transplantation, standardization of at least some central procedures would be needed. As the first step, the European Group for Blood and Marrow Transplantation (EBMT) performed a survey among all its 372 member centres performing allogeneic transplantations about their strategies in preventing and treating GVHD. Responses from 79 centres (21% return) from 25 countries (60% return) were received. Although some trends toward more uniform policies compared with a survey carried out 15 years earlier were observed, the present survey still showed marked variability in the GVHD prophylaxis and treatment strategies. On the basis of these findings, EBMT is developing a consensus process aiming at a standardized strategy.
Similar content being viewed by others
References
Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 116: 4715–4726.
Ruutu T, Niederwieser D, Gratwohl A, Apperley JF . A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759–764.
Bacigalupo A, van Lint MT, Occhini D, Gualandi F, Lamperelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–1428.
Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low dose cyclosporine reduces the risk of relapse in children with acute leukemia given HLA identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572–1579.
Bacigalupo A . Management of acute graft-versus-host disease. Br J Haematol 2007; 137: 87–98.
Ferrara JLM, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550–1561.
Inamoto Y, Flowers MED, Lee SJ, Carpenter PA, Warren EH, Deeg J et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood 2011; 118: 456–463.
Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219–234.
Goldman J . Special report: bone marrow transplants using volunteer donors, recommendations and requirements for a standardized practice throughout the world—1994 update. Blood 1994; 84: 2833–2839.
World Marrow Donor Association International standards for unrelated hematopoietic stem cell donor registries. www.worldmarrow.org,_Standards_December_2007.pdf.
Clift RA, Buckner CD, Appelbaum FA, Bearman SI, Petersen FE, Fisher LD et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990; 76: 1867–1871.
Pavlů J, Szydlo RM, Goldman JM, Apperley JF . Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011; 117: 755–763.
Frassoni F, Labopin M, Powles R, Mary J-Y, Arcese W, Bacigalupo A et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Lancet 2000; 355: 1393–1398.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Appendix
Appendix
Participating centres
Austria
Medical University Graz, Department of Internal Medicine, Division of Hematology
Medizinische Universität Wien, Klinik für Innere Medizin, Knochenmarktransplantation
Belgium
Antwerp University Hospital (UZA), Department of Hematology, Antwerp Edegem
Cliniques Universitaires St Luc, Department of Haematology, Brussels
University Hospital VUB, Department of Medical Oncology/Hematology, Brussels
University Hospital Gasthuisberg, Department of Hematology, Leuven
University of Liege, Department of Hematology
Brasil
Universidade Estadual de Campinas/TMO/UNICAMP, Cidade Universitaria ‘Zeferino Vaz’, Campinas
Croatia
University Hospital Center Rebro, Zagreb
Czech Republic
Charles University Hospital, Department of Hematology/Oncology, Pilsen
Institute of Hematology and Blood Transfusion, Prague
Denmark
Rigshospitalet, BMT Unit, Department of Hematology, Copenhagen
Estonia
Tartu University Hospital, Clinic of Hematology and Oncology
Finland
Helsinki University Central Hospital, Department of Medicine, Division of Haematology
France
CHRU, Service des Maladies du Sang, Angers
Hopital E. Herriot, BMT Unit, Lyon
Hopital Saint Antoine, Department of Hematology, Paris
Hopital Bretonneau, Service d'Oncologie Médical, Tours
Germany
Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik m.S. Hämatologie/Onkologie
University Hospital Erlangen, Department of Medicine 5
University of Freiburg, Department of Medicine-Hematology, Oncology
Ernst-Moritz-Arndt-Universität Greifswald, Medizinische Universitätsklinik C
Martin-Luther-Universität Halle-Wittenberg, BMT Section, State Center for Cell and Gene Therapy, Department of Internal Medicine IV, Halle
University Hospital Eppendorf, Bone Marrow Transplantation Centre, Hamburg
Hannover Medical University, Department of Hematology/Oncology
University of Heidelberg, Medizinische Klinik und Poliklinik V
Friedrich-Schiller-Universität Jena, Klinik für Innere Medizin II
Klinikum Karlsruhe gGmbH, II Medizinische Klinik, Hämatologie, Onkologie
Universität Rostock, Klinik für Innere Medizin/Hämatologie/Onkologie
Deutsche Klinik für Diagnostik, KMT Zentrum, Wiesbaden
Greece
George Papanicolaou General Hospital, Haematology Department/BMT Unit, Thessaloniki
Ireland
St James Hospital Trinity College, Department of Hematology, Dublin
Israel
Beilinson Hospital, Hematology and BMT Department, Petach-Tikva
Chaim Sheba Medical Center, Tel-Hashomer
Italy
Azienda Ospedali Riuniti di Ancona, Clinica di Ematologia, Ancona-Torrete
Bologna University, S.Orsola-Malpighi Hospital, Institute of Hematology and Medical Oncology L and A Seràgnoli
Ospedale Ferrarotto, Divisione Clinicizzata di Ematologia, Catania
Ospedale di Careggi, BMT Unit, Department of Hematology, Firenze
Ospedale San Gerardo, Clinica Ematologica dell'Universita Milano-Biocca, Monza
Humanitas Cancer Center, Transplantation Unit, Department of Oncology-Hematology, Milano
Azienda Ospedaliera, Centro Unico Regionale Trapianti, Reggio Calabria
Universita Cattolica S Cuore, Istituto di Ematologia, Rome
Lebanon
American University of Beirut, Department of Internal Medicine
The Netherlands
University Medical Center Groningen, Department of Hematology
University Hospital Maastricht, Department of Internal Medicine, Hematology/Oncology
University Medical Centre, Department of Haematology, Utrecht
New Zealand
Canterbury Health Laboratories, Department of Haematology, Christchurch
Wellington Regional Bone Marrow Transplant Unit, Wellington Hospital
Norway
Haukeland University Hospital, Department of Haematology, Bergen
Rikshospitalet, Department of Medicine, Oslo
Poland
University Hospital, Collegium Medicum UMK, Pediatric Hematology and Oncology, Bydgoszcz
Lower Silesian Centre for Cellular Transplantation with National Bone Marrow Donor Registry, Wroclaw
Slovenia
University Medical Center, Department of Hematology, Ljubljana
Spain
Hospital Universitari Germans Trias i Pujol, Barcelona
Hospital Vall d'Hebron, Unidad de Adultos, Barcelona
University Hospital of Asturias, Clinical Hematology Department, Oviedo
Hospital de Navarra, Servicio de Hematologia, Pamplona
Hospital U Marqués de Valdecilla, Servicio de Hematologia-Hemoterapia, Santander
Sweden
University Hospital, Department of Hematology, Linköping
University Hospital, Department of Hematology, Lund
Karolinska University Hospital, Centre for Allogeneic Stem Cell Transplantation Huddinge, Stockholm
Umeå University Hospital, Hematology
University Hospital, Department of Medicine, Uppsala
Switzerland
University Hospital, Hematology, Basel
Hopitaux Universitaires de Geneve, Departement Medecine Interne, Geneva
University Hospital, Clinic of Hematology, Zürich
Turkey
Akdeniz University Medical School, Department of Pediatric Hematology, Antalya
Medical Park Hospitals, Stem Cell Transplant Unit, Antalya
Ankara University Faculty of Medicine, Department of Hematology, Adult Stem Cell Transplantation Unit
Gazi Universitesi Tip Fakültesi Hastanesi, Eriskin Hematoloji Bilim Dali, Ankara
United Kingdom
Belfast City Hospital, Department of Haematology
University of Wales, College of Medicine, Department of Haematology, Cardiff
Bone Marrow Transplant Unit, Beatson, West of Scotland Cancer Centre, Glasgow
Leicester Royal Infirmary, Department of Haematology
Royal Liverpool University Hospital, Department of Haematology
Guy's Hospital, Department of Haematology, London
Imperial College, Department of Haematology, Hammersmith Hospital, London
Christie NHS Trust Hospital, Adult Leukaemia and Bone Marrow Transplant Unit, Manchester
Nottingham City Hospital
Rights and permissions
About this article
Cite this article
Ruutu, T., van Biezen, A., Hertenstein, B. et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47, 1459–1464 (2012). https://doi.org/10.1038/bmt.2012.45
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.45
- Springer Nature Limited
Keywords
This article is cited by
-
Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment
Bone Marrow Transplantation (2024)
-
Higher cyclosporine-A concentration increases the risk of relapse in AML following allogeneic stem cell transplantation from unrelated donors using anti-thymocyte globulin
Scientific Reports (2023)
-
Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin
Bone Marrow Transplantation (2022)
-
Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study
Bone Marrow Transplantation (2022)
-
Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT
Bone Marrow Transplantation (2021)